1-4 of 4
Karen Kaucic, MD
Close
Sort by
Journal Articles

Population Pharmacokinetics of Siplizumab (MEDI-507), a Humanized Anti-CD2 Monoclonal Antibody, in Cancer Patients.

Chunlin Chen, MD, PhD, John E Janik, MD, Karen Kaucic, MD, Lorin Roskos, PhD, Bahija Jallal, PhD, Gabriel J. Robbie, PhD
Journal: Blood
Blood (2009) 114 (22): 2670.
https://doi.org/10.1182/blood.V114.22.2670.2670
Published: 2009
Journal Articles

Phase I Clinical Trial of the Anti-CD22 Immunotoxin CAT-8015 (HA22) for Pediatric Acute Lymphoblastic Leukemia (ALL).

Alan S. Wayne, MD, Deepa Bhojwani, MD, Sima Jeha, MD, Maryalice Stetler-Stevenson, MD, PhD, Ching-Hon Pui, MD, Jennifer McDevitt, PharmD, PhD, David J. FitzGerald, Robert J Kreitman, MD, Karen Kaucic, MD, Ira Pastan
Journal: Blood
Blood (2009) 114 (22): 839.
https://doi.org/10.1182/blood.V114.22.839.839
Published: 2009
Journal Articles

Phase I Dose-Escalation Study of CAT-8015 (HA22), A CD22-Specific Targeted Immunotoxin, in Relapsed or Refractory Hairy Cell Leukemia.

Robert J Kreitman, MD, Martin S. Tallman, MD, Steven Coutre, MD, Tadeusz Robak, MD, PhD, Wyndham H Wilson, MD, PhD, Maryalice Stetler-Stevenson, MD, PhD, Pierre Noel, MD, David J. FitzGerald, PhD, Manuela Buzoianu, PhD, Robert Lechleider, MD, Karen Kaucic, MD, Ira Pastan, MD
Journal: Blood
Blood (2009) 114 (22): 888.
https://doi.org/10.1182/blood.V114.22.888.888
Published: 2009
Journal Articles

EBV-Related Lymphoproliferative Disease Complicating Therapy with Siplizumab, a Novel Anti-CD2 Mediated T- and NK-Cell Depleting Agent, in Patients with T-Cell Malignancies.

Deirdre O’Mahony, MD, John C. Morris, MD, Maryalice Stetler-Stevenson, MD, Helen Matthews, RN, Stefania Pittaluga, MD, Paul Albert, PhD, Karen Kaucic, MD, Luz Hammershaimb, MD, Thomas A. Waldmann, MD, John E. Janik, MD
Journal: Blood
Blood (2007) 110 (11): 3565.
https://doi.org/10.1182/blood.V110.11.3565.3565
Published: 2007